Abstract
Despite the rapidly growing knowledge of functional and structural information regarding pharmaceutically relevant targets during the past decade, target-based drug discovery has remained a high-cost and low-yield process. Particularly, single-target drugs often turn out to be less effective in treating complicated diseases such as cancers, metabolic disorders and CNS diseases. However, discovering compounds that are effective against multiple desired targets raises an enormous challenge to the current mode of drug innovation. Computational chemogenomics approaches aim at predicting all potential interactions between small molecular ligands and biomolecular targets, thus the derived information can be directly applied to “design in” (i.e. engineer desirable binding spectrum) and “design out” (i.e. eliminate the unwanted interactions) specific biological activities. The present review will focus on introducing the recent methodological development and successful applications of structure-based and ligand-based approaches on predicting the ligand binding profiles, which is the very first and essential step toward rationally designing the multiple-target ligands. Structure-based methods (e.g. binding site mapping and inverse molecular docking) generally require the structures of known targets to navigate the receptor-ligand binding space, while ligand-based approaches (e.g. chemical similarity analysis and pharmacophore search) can only rely on the series of active compounds to derive the structural characteristics for describing certain biological activities.
Keywords: binding free energy, chemoinformatics, computational chemogenomics, molecular docking, multiple-target ligand, pharmacophore search, similarity search, target-based drug discovery, CNS diseases, multiple desired targets
Current Topics in Medicinal Chemistry
Title:Identifying Multiple-target Ligands via Computational Chemogenomics Approaches
Volume: 12 Issue: 12
Author(s): Shiming Peng, Xingyu Lin, Zongru Guo and Niu Huang
Affiliation:
Keywords: binding free energy, chemoinformatics, computational chemogenomics, molecular docking, multiple-target ligand, pharmacophore search, similarity search, target-based drug discovery, CNS diseases, multiple desired targets
Abstract: Despite the rapidly growing knowledge of functional and structural information regarding pharmaceutically relevant targets during the past decade, target-based drug discovery has remained a high-cost and low-yield process. Particularly, single-target drugs often turn out to be less effective in treating complicated diseases such as cancers, metabolic disorders and CNS diseases. However, discovering compounds that are effective against multiple desired targets raises an enormous challenge to the current mode of drug innovation. Computational chemogenomics approaches aim at predicting all potential interactions between small molecular ligands and biomolecular targets, thus the derived information can be directly applied to “design in” (i.e. engineer desirable binding spectrum) and “design out” (i.e. eliminate the unwanted interactions) specific biological activities. The present review will focus on introducing the recent methodological development and successful applications of structure-based and ligand-based approaches on predicting the ligand binding profiles, which is the very first and essential step toward rationally designing the multiple-target ligands. Structure-based methods (e.g. binding site mapping and inverse molecular docking) generally require the structures of known targets to navigate the receptor-ligand binding space, while ligand-based approaches (e.g. chemical similarity analysis and pharmacophore search) can only rely on the series of active compounds to derive the structural characteristics for describing certain biological activities.
Export Options
About this article
Cite this article as:
Peng Shiming, Lin Xingyu, Guo Zongru and Huang Niu, Identifying Multiple-target Ligands via Computational Chemogenomics Approaches, Current Topics in Medicinal Chemistry 2012; 12 (12) . https://dx.doi.org/10.2174/156802612801319016
DOI https://dx.doi.org/10.2174/156802612801319016 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Adaptogens—History and Future Perspectives
Adaptogens are pharmacologically active compounds or plant extracts that are associated with the ability to enhance the body’s stability against stress. The intake of adaptogens is associated not only with a better ability to adapt to stress and maintain or normalise metabolic functions but also with better mental and physical ...read more
Addressing the Most Common Causes of Death with Niacin/NAD and Inositol Polyphosphates
The most common causes of death in the world are cardiovascular disease (CVD) and cancer. These are perhaps best addressed by reducing lipodystrophy and blockages with niacin and inositol polyphosphates (e.g., IP6+inositol) respectively when addressing CVD. Niacin serves as a vitamin by virtue of its role as a skeletal precursor ...read more
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Diabetic Cardiomyopathy: Electromechanical Cellular Alterations
Current Vascular Pharmacology In Vitro and In Vivo Sirolimus for Modulation of Allogeneic Hematopoietic Stem Cell Transplantation
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Biochemical Markers for Brain Injury Monitoring in Children with or without Congenital Heart Diseases
CNS & Neurological Disorders - Drug Targets Gene Therapy for Familial Hypercholesterolemia
Current Pharmaceutical Design The Role of T-Type Calcium Channels in Epilepsy and Pain
Current Pharmaceutical Design Recent Advance in the Pharmacology of Dihydropyrimidinone
Mini-Reviews in Medicinal Chemistry Rate and Predictors of Permanent Pacemaker Implantation After Transcatheter Aortic Valve Implantation: Current Status
Current Cardiology Reviews Protein Kinase C Pharmacology: Perspectives on Therapeutic Potentials as Antidementic and Cognitive Agents
Recent Patents on CNS Drug Discovery (Discontinued) Bone Disruption and Environmental Pollutants
Endocrine, Metabolic & Immune Disorders - Drug Targets The Immunomodulatory Effects of Physical Activity
Current Pharmaceutical Design Trafficking of Neuronal Two Pore Domain Potassium Channels
Current Neuropharmacology Exercise Training-Associated Changes in Arterial Stiffness and Endothelium-Derived Vasoactive Factors
Current Hypertension Reviews Adrenal Hyperandrogenism and Polycystic Ovary Syndrome
Current Pharmaceutical Design Phosphoinositide-3-kinases as the Novel Therapeutic Targets for the Inflammatory Diseases: Current and Future Perspectives
Current Drug Targets Renal Protective Effect of Metabolic Therapy in Patients with Coronary Artery Disease and Diabetes: From Bench to Bed Side
Current Pharmaceutical Design Diagnosis and Prognosis of Fetal Cardiomyopathies: A Review
Current Pharmaceutical Design The Phosphoinositide 3-Kinase (PI3K)/AKT Signaling Pathway as a Therapeutic Target for the Treatment of Human Acute Myeloid Leukemia (AML)
Current Signal Transduction Therapy Tandem Pore Domain K Channels An Important Site of Volatile Anesthetic Action
Current Drug Targets Clinical Utility of Biomarkers in Premature Atherosclerosis
Current Medicinal Chemistry Substrates and Inhibitors of Human Multidrug Resistance Associated Proteins and the Implications in Drug Development
Current Medicinal Chemistry